Oncology Institute (NASDAQ:TOI) Trading Up 1.3%

The Oncology Institute, Inc. (NASDAQ:TOI – Get Rating) shares were up 1.3% on Wednesday . The stock traded as high as $0.48 and last traded at $0.43. Approximately 468,333 shares were traded during mid-day trading, an increase of 187% from the average daily volume of 163,166 shares. The stock had previously closed at $0.42.

Analyst Upgrades and Downgrades

Separately, Guggenheim lowered their target price on shares of Oncology Institute from $6.00 to $3.00 in a research note on Monday, March 20th.

Oncology Institute Stock Up 1.3 %

The company’s 50 day moving average price is $0.57 and its 200 day moving average price is $1.18. The company has a quick ratio of 3.61, a current ratio of 3.95 and a debt-to-equity ratio of 0.83. The firm has a market capitalization of $32.05 million, a price-to-earnings ratio of -0.60 and a beta of 0.87.

Oncology Institute (NASDAQ:TOI – Get Rating) last posted its earnings results on Thursday, March 9th. The company reported ($0.16) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.18) by $0.02. The company had revenue of $71.42 million during the quarter, compared to the consensus estimate of $65.46 million. Oncology Institute had a negative net margin of 17.41% and a negative return on equity of 26.61%. As a group, research analysts forecast that The Oncology Institute, Inc. will post -0.63 earnings per share for the current fiscal year.

Insider Activity at Oncology Institute

In other news, Director Richard A. Barasch acquired 50,000 shares of the business’s stock in a transaction on Friday, March 17th. The stock was bought at an average price of $0.55 per share, with a total value of $27,500.00. Following the completion of the acquisition, the director now owns 257,193 shares of the company’s stock, valued at $141,456.15. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 10.40% of the stock is currently owned by insiders.

Institutional Trading of Oncology Institute

Institutional investors and hedge funds have recently modified their holdings of the stock. American International Group Inc. acquired a new position in Oncology Institute during the second quarter worth about $44,000. Bank of America Corp DE acquired a new position in Oncology Institute during the first quarter worth about $69,000. JPMorgan Chase & Co. boosted its position in Oncology Institute by 2,410.3% during the second quarter. JPMorgan Chase & Co. now owns 10,041 shares of the company’s stock worth $51,000 after acquiring an additional 9,641 shares during the last quarter. Allspring Global Investments Holdings LLC acquired a new position in Oncology Institute during the third quarter worth about $50,000. Finally, California State Teachers Retirement System boosted its position in Oncology Institute by 71.0% during the third quarter. California State Teachers Retirement System now owns 13,734 shares of the company’s stock worth $64,000 after acquiring an additional 5,703 shares during the last quarter. Hedge funds and other institutional investors own 70.45% of the company’s stock.

Oncology Institute Company Profile

(Get Rating)

The Oncology Institute, Inc, an oncology company, provides medical oncology services in the United States. Its services include physician services, in-house infusion and dispensary, clinical trial services, radiation, outpatient stem cell transplants and transfusions programs, and patient support. The company also offers and manages clinical trial services, such as managing clinical trials, palliative care programs, and stem cell transplants services.